Common use of DESCRIPTION OF WARRANTS Clause in Contracts

DESCRIPTION OF WARRANTS. We may issue warrants to purchase shares of our common stock or preferred stock in one or more series together with other securities or separately, as described in each applicable prospectus supplement. Below is a description of certain general terms and provisions of the warrants that we may offer. Particular terms of the warrants will be described in the applicable warrant agreements and the applicable prospectus supplement for the warrants. As of September 30, 2021, we had warrants outstanding that represent the right to acquire 39,474 shares of common stock. The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants: • the specific designation and aggregate number of, and the price at which we will issue, the warrants; • the currency or currency units in which the offering price, if any, and the exercise price are payable; • if applicable, the exercise price for shares of our common stock and the number of shares of common stock to be received upon exercise of the warrants; • if applicable, the exercise price for shares of our preferred stock, the number of shares of preferred stock to be received upon exercise, and a description of that class or series of our preferred stock; • the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if the warrants may not be continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised; • whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; • any applicable material U.S. federal income tax consequences; • the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents; • the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; • if applicable, the date from and after which the warrants and the common stock and/or preferred stock will be separately transferable; • if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; • information with respect to book-entry procedures, if any; • the anti-dilution provisions of the warrants, if any; • any redemption or call provisions; • whether the warrants are to be sold separately or with other securities as parts of units; and • any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. Transfer Agent and Registrar The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.

DESCRIPTION OF WARRANTS. We may issue warrants to purchase ordinary shares, preferred shares, depositary shares of our common stock or preferred stock in debt securities. We may offer warrants separately or together with one or more series together with other additional warrants, ordinary shares, preferred shares, depositary shares or debt securities, or any combination of those securities or separatelyin the form of units, as described in each the applicable prospectus supplement. Below is If we issue warrants as part of a description of certain general terms and provisions unit, the accompanying prospectus supplement will specify whether those warrants may be separated from the other securities in the unit prior to the expiration date of the warrants that we may offer. Particular terms of the warrants will be described in the applicable warrant agreements and the applicable prospectus supplement for the warrants. As of September 30, 2021, we had warrants outstanding that represent the right to acquire 39,474 shares of common stock. The applicable prospectus supplement will contain, where applicable, also describe the following terms of and other information relating to the any warrants: • the specific designation and aggregate number of, and the offering price at which we will issue, the warrants; • the currency or currency units in which the offering price, if any, and the exercise price are payable; • if applicable, the exercise price for shares of our common stock and the number of shares of common stock to be received upon exercise of the warrants; • if applicable, the exercise price for shares of our preferred stock, the number of shares of preferred stock to be received upon exercise, and a description of that class or series of our preferred stock; • the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously exercise the warrants may not be continuously exercised throughout that period, the specific date or dates on which you may exercise the warrants; • whether the warrants may are to be exercisedsold separately or with other securities as parts of units; • whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; • any applicable material U.S. federal income tax consequences; • the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents; • the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; • the designation and terms of any equity securities purchasable upon exercise of the warrants; • the designation, aggregate principal amount, currency and terms of any debt securities that may be purchased upon exercise of the warrants; • if applicable, the designation and terms of the preferred shares or depositary shares with which the warrants are issued and the number of warrants issued with each security; • if applicable, the date from and after which the any warrants issued as part of a unit and the common stock and/or related debt securities, preferred stock shares, depositary shares or ordinary shares will be separately transferable; • the number of ordinary shares, preferred shares or depositary shares purchasable upon exercise of a warrant and the price at which those shares may be purchased; • if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; • information with respect to book-entry procedures, if any; • the anti-dilution provisions of of, and other provisions for changes to or adjustment in the exercise price of, the warrants, if any; • any redemption or call provisions; • whether the warrants are to be sold separately or with other securities as parts of units; and • any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and or exercise of the warrants. Transfer Agent and Registrar The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.

DESCRIPTION OF WARRANTS. We may issue warrants to purchase our ordinary shares of our common stock or preferred stock in one or more series together with other securities or separately, as described in each the applicable prospectus supplement. Below is Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a warrant agent. The warrant agent will act solely as our agent and will not assume any obligation or relationship of agency for or with holders or beneficial owners of warrants. The terms of any warrants to be issued and a description of certain general terms and the material provisions of the warrants that we may offer. Particular terms of the warrants applicable warrant agreement will be described set forth in the applicable warrant agreements and the applicable prospectus supplement for the warrants. As of September 30, 2021, we had warrants outstanding that represent the right to acquire 39,474 shares of common stocksupplement. The applicable prospectus supplement will contain, where applicable, describe the following terms of and other information relating to the warrantsany warrants in respect of which this prospectus is being delivered: • the specific designation and aggregate number of, and the price at which we will issue, the title of such warrants; • the currency aggregate number of such warrants; • the price or currency units in prices at which such warrants will be issued; • the offering price, if anyprice at which, and the exercise price are payable; • if applicablecurrency or currencies in which, the exercise price for shares of our common stock and the number of shares of common stock to be received securities upon exercise of the warrantssuch warrants may be purchased; • if applicablethe designation, amount and terms of the securities purchasable upon exercise price for shares of our preferred stock, the number of shares of preferred stock to be received upon exercise, and a description of that class or series of our preferred stocksuch warrants; • the date on which the right to exercise the such warrants will begin shall commence and the date on which that such right will expire or, if the warrants may not be continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised; • whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; • any applicable material U.S. federal income tax consequences; • the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents; • the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; • if applicable, the date from and after which the warrants and the common stock and/or preferred stock will be separately transferableshall expire; • if applicable, the minimum or maximum amount of the such warrants that which may be exercised at any one time; • if applicable, the designation and terms of the securities with which such warrants are issued and the number of such warrants issued with each such security; • if applicable, the date on and after which such warrants and the related securities will be separately transferable; • information with respect to book-entry procedures, if any; • if applicable, any material Israeli and U.S. federal income tax considerations; • the anti-dilution provisions of the such warrants, if any; • any redemption or call provisions; • whether the warrants are to be sold separately or with other securities as parts of units; and • any additional other terms of the such warrants, including terms, procedures and limitations relating to the exchange and exercise of the such warrants. Transfer Agent and Registrar The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.

DESCRIPTION OF WARRANTS. We may issue warrants to for the purchase shares of our preferred stock, common stock stock, or preferred stock in one any combination thereof. We may issue warrants independently or more series together with any other securities offered by any prospectus supplement and may be attached to or separately, separate from the other offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into by us with a warrant agent. The warrant agent will act solely as described our agent in each applicable prospectus supplement. Below is a description of certain general terms and provisions of connection with the warrants that we may offerand will not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. Particular Further terms of the warrants will be described in and the applicable warrant agreements and will be set forth in the applicable prospectus supplement for the warrants. As of September 30, 2021, we had warrants outstanding that represent the right to acquire 39,474 shares of common stocksupplement. The applicable prospectus supplement relating to any particular issue of warrants will containdescribe the terms of the warrants, where including, as applicable, the following terms following: · the title of and other information relating to the warrants: • the specific designation and aggregate number of, and the price at which we will issue, the warrants; • · the currency aggregate number of the warrants; · the price or currency units in prices at which the offering pricewarrants will be issued; · the designation, if any, terms and the exercise price are payable; • if applicable, the exercise price for shares of our common stock and the number of shares of preferred stock or common stock to be received purchasable upon exercise of the warrants; • · the designation and terms of the offered securities, if applicableany, with which the exercise price for shares of our preferred stock, warrants are issued and the number of shares the warrants issued with each offered security; · the date, if any, on and after which the warrants and the related preferred stock or common stock will be separately transferable; · the price at which each share of preferred stock to or common stock purchasable upon exercise of the warrants may be received upon exercise, and a description of that class or series of our preferred stockpurchased; • · the date on which the right to exercise the warrants will begin shall commence and the date on which that right will expire or, if the warrants may not be continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised; • whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; • any applicable material U.S. federal income tax consequences; • the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents; • the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; • if applicable, the date from and after which the warrants and the common stock and/or preferred stock will be separately transferable; • if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; • information with respect to book-entry procedures, if any; • the anti-dilution provisions of the warrants, if any; • any redemption or call provisions; • whether the warrants are to be sold separately or with other securities as parts of units; and • any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. Transfer Agent and Registrar The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.shall expire;